quinta-feira, 12 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 28, 2026

Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook

View original at finance.yahoo.com
Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 237 more high quality undervalued stocks are identified on Simply Wall St's platform

    60% confidence

  • Novo Nordisk is undervalued by 65.4% based on DCF analysis, with an intrinsic value of DKK 769.11 per share

    60% confidence

  • Novo Nordisk extrapolated Free Cash Flow reaches approximately DKK 145.9 billion by 2035

    60% confidence

  • Sell-side analysts have provided explicit Free Cash Flow forecasts for Novo Nordisk out to 2030, with Simply Wall St extrapolating further to 2035

    60% confidence

  • Novo Nordisk projected Free Cash Flow reaches DKK 107.4 billion by 2030

    60% confidence

  • Investors have been reassessing Novo Nordisk's growth expectations and risk, shifting sentiment and explaining the mix of short-term gains and long-term declines

    60% confidence

  • Novo Nordisk scores 5 out of 6 on Simply Wall St's valuation checks

    60% confidence

  • Novo Nordisk's 34.5% return over the last year is lagging behind its pharmaceutical peers

    60% confidence

Data points we hold from this source

Novo Nordisk · free cash flow52.1 billion_DKK
Novo Nordisk · free cash flow projected107.4 billion_DKK
Novo Nordisk · free cash flow extrapolated145.9 billion_DKK
Novo Nordisk · dcf intrinsic value769.11 DKK_per_share
Novo Nordisk · discount to intrinsic value65.4 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,565 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook — Source | Via News | pt.VIA.NEWS